1,3-diphenyl-4-pyrazolecarbonitrile is an organic compound with the molecular formula C16H11N3. It is a white solid that is soluble in organic solvents. This compound is important for research because of its potential applications in several fields:
**1. Medicinal Chemistry:**
* **Anti-inflammatory Activity:** 1,3-diphenyl-4-pyrazolecarbonitrile has been shown to exhibit anti-inflammatory activity in various studies. It can inhibit the production of inflammatory mediators like prostaglandins and leukotrienes, making it a potential lead compound for developing new anti-inflammatory drugs.
* **Antimicrobial Activity:** This compound has also been found to possess antimicrobial activity against certain bacteria and fungi, suggesting its potential use in developing new antibiotics or antifungal agents.
* **Anti-cancer Activity:** Research indicates that 1,3-diphenyl-4-pyrazolecarbonitrile might have anti-cancer activity by interfering with the growth and proliferation of cancer cells.
* **Other Potential Applications:** This compound has also been investigated for its potential as an analgesic (pain reliever), anticonvulsant, and anti-diabetic agent.
**2. Material Science:**
* **Luminescence:** 1,3-diphenyl-4-pyrazolecarbonitrile exhibits fluorescence properties, making it a potential candidate for applications in organic light-emitting diodes (OLEDs) and other optoelectronic devices.
**3. Organic Synthesis:**
* **Building Block:** 1,3-diphenyl-4-pyrazolecarbonitrile serves as a valuable building block for the synthesis of other complex organic molecules. Its nitrile group can be readily converted into various functional groups, allowing for the development of diverse derivatives with specific properties.
**Importance for Research:**
* **Lead Compound Development:** Due to its diverse biological activities, 1,3-diphenyl-4-pyrazolecarbonitrile is an attractive lead compound for the development of new drugs and therapies.
* **Structure-Activity Relationship Studies:** Researchers can use this compound as a template to investigate the structure-activity relationship of pyrazole derivatives. Modifying the structure of this molecule can lead to the discovery of new compounds with enhanced potency or selectivity for specific targets.
* **New Material Development:** The fluorescence property of this compound opens up possibilities for developing novel organic materials for optoelectronic devices and sensors.
* **Organic Chemistry Research:** 1,3-diphenyl-4-pyrazolecarbonitrile's synthetic versatility makes it a valuable tool for exploring new organic synthesis methods and reactions.
**Note:** Research on 1,3-diphenyl-4-pyrazolecarbonitrile is ongoing, and its full potential remains to be explored. While it shows promise in various fields, further investigations are necessary to validate its therapeutic and material science applications.
ID Source | ID |
---|---|
PubMed CID | 700979 |
CHEMBL ID | 1536809 |
CHEBI ID | 121099 |
Synonym |
---|
IFLAB1_001551 |
smr000060512 |
MLS000098769 , |
CHEBI:121099 |
HMS1416G11 |
AKOS001010375 |
1,3-diphenylpyrazole-4-carbonitrile |
HMS2472O04 |
1,3-diphenyl-1h-pyrazole-4-carbonitrile |
1h-pyrazole-4-carbonitrile, 1,3-diphenyl- |
17647-21-1 |
cid_700979 |
1,3-diphenyl-4-pyrazolecarbonitrile |
bdbm49022 |
CHEMBL1536809 |
Q27209342 |
DTXSID70351470 |
Z56813172 |
Class | Description |
---|---|
ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
pyrazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 8.4921 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 0.3162 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 8.9125 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 5.0119 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
67.9K protein | Vaccinia virus | Potency | 20.3865 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
geminin | Homo sapiens (human) | Potency | 0.0651 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |